Latvia pharmaceuticals market will stagnate at $377 million in 2010, says BMI, due to govt austerity measures
Latvia's pharmaceutical market is currently overshadowed by sharp cuts as part of the government’s austerity package, which is aimed at securing European Union and International Monetary Fund financing. The country's economy may now be showing signs of a meek recovery but further cuts will help play out Business Monitor International's view that the pharmaceutical market will stagnate at 236 million lats ($377 million) in 2010.
Health care expenditure has been slashed by the government in a desperate effort to remain eligible for emergency loan packages, as well in preparation for potential euro-membership. The concomitant decline of the health care sector will see total drugs expenditure in 2010 remain flat against 2009 levels, while per capita expenditure will slim to $168.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze